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Abstract
Background: Recent studies have shown that microRNAs (miRNAs) play roles in tumorigenesis and are reliable 
classifiers of certain cancer types and subtypes. However, the role of miRNAs in the pathogenesis and diagnosis of 
small cell carcinoma (SCLC), the majority of which represent the most aggressive lung tumors, has not been 
investigated.
Methods: In order to explore miRNA involvement in the pathogenesis of small cell lung carcinoma (SCLC) and the 
potential role of miRNAs in SCLC diagnosis, we compared the miRNA expression profile of a set of SCLC cell lines to that 
of a set of non-small cell lung cancer (NSCLC) cell lines and normal immortalized human bronchial epithelial cells 
(HBECs) using microarray analysis.
Results: Our results show that miRNA profiles reliably distinguish SCLC cell lines from NSCLC and HBEC cell lines. 
Further analysis of the miRNA expression profile of the two subtypes of lung cancer cell lines indicates that the 
expression levels of the majority of the miRNAs that are differentially expressed in SCLC cells relative to NSCLC cells and 
HBECs show a progressive trend from HBECs to NSCLC cells to SCLC cells.
Conclusions: The distinctive miRNA expression signature of SCLCs relative to NSCLCs and HBECs suggests that miRNA 
profiles have the potential to serve as a diagnostic marker of SCLC lung tumors. The progressive trend of miRNA profile 
changes from HBECs to NSCLCs to SCLCs suggests a possible pathological relationship between SCLCs and NSCLCs, 
and suggests that the increasing dysregulation of miRNA expression may play a role in lung tumor progression. The 
specific role of these miRNAs in lung tumor pathogenesis and differentiation need to be investigated further in future 
studies.
Background
Small cell lung carcinoma (SCLC) is the most aggressive
subtype of all lung tumors [1]. The poor survival rate of
patients with SCLC is largely due to late detection and
the lack of therapeutic regimens specifically targeted to
SCLC [2,3]; thus, therapeutic improvement depends on a
better understanding of the mechanisms underlying
SCLC tumorigenesis and developing targeted therapy for
this class of lung cancers. Although decades of work have
led to better understanding of the genetic abnormalities
in SCLC [1,4], these still cannot completely explain the
aggressive phenotype that distinguishes it from other
lung cancer subtypes. There is clearly an urgent need for
continued efforts to understand SCLC tumorigenesis and
to identify early diagnostic markers and therapeutic tar-
gets for SCLC.
A recently discovered class of small noncoding RNAs,
microRNAs (miRNAs), regulates gene expression pri-
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marily by binding to sequences in the 3' untranslated
region (3'UTR) of expressed mRNAs, resulting in
decreased protein expression either by repression of
translation or by enhancement of mRNA degradation.
miRNAs have been shown to have a variety of regulatory
functions and to play roles in controlling cancer initiation
and progression [5]. Many studies have demonstrated
dysregulation of particular miRNAs in various cancer
types and investigated the mechanisms of specific miR-
NAs in tumorigenesis [5-7]. In the context of lung cancer,
several studies have attempted to distinguish the miRNA
profiles of histological subtypes showing the potential of
miRNA profiles as diagnostic markers for distinguishing
specific subtypes, such as squamous cell carcinoma and
adenocarcinoma [8,9]. Moreover, tumor suppressor
genes and oncogenes that play crucial roles in lung tum-
origenesis have been demonstrated to be targets of miR-
NAs [10-12], and manipulation of miRNA levels has been
used to control lung cancer cell survival and proliferation
in vitro and in vivo [13-16]. Few studies, however, have
focused on the role of miRNAs in the pathogenesis of
SCLC [17]. Primary tissue specimens are difficult to
obtain as most SCLC tumors are not surgically resected
[4,18], underscoring the importance of cell lines for
studying this disease [19,20]. In order to characterize the
expression of miRNAs in SCLC and explore the potential
role of miRNAs in SCLC tumorigenesis, we profiled and
compared the expression levels of a group of miRNAs in a
set of lung cancer cell lines, including SCLC and non-
small cell lung cancer (NSCLC) cell lines and immortal-
ized human bronchial epithelial cells (HBECs).
Materials and methods
Cell lines
19 cell lines (Table 1), including 16 lung cancer cell lines
[21], and 3 HBEC cell lines immortalized via ectopic
expression of cdk4 and hTERT [22], were obtained from
the Hamon Center for Therapeutic Oncology Research at
UT Southwestern Medical Center. All cancer cell lines
were grown in RPMI-1640 medium (Sigma, St. Louis,
MO) supplemented with 5% fetal bovine serum. HBECs
were grown in KSFM medium supplemented with bovine
pituitary extract and recombinant human epidermal
growth factor (Gibco, Carlsbad, CA). All cell lines were
grown in a humidified atmosphere with 5% CO2 at 37°C.
RNA isolation and miRNA microarray
Total RNA was extracted using TRIzol (Invitrogen, Carls-
bad, CA), and labeled with a fluorescent modified dinu-
cleotide (5'-phosphate-cytidyl-uridyl-Cy3-3') using T4
RNA ligase, according to Thomson [23]. Oligonucleotide
probes antisense to the published mature sequences for
136 conserved human miRNAs were synthesized and
spotted in duplicate on Corning GAPS-2 coated slides
using a robotic spotter [23]. Samples were hybridized to
the array, along with an equimolar reference oligonucle-
otide set corresponding to the 136 mature microRNAs,
which had been labeled with Cy5. Array images were
obtained and analyzed with a GenePix 4000A scanner
and GenePix Pro 4.1 software (Axon Instruments). We
measured raw signal at 532 nm (Cy3) and 635 nm (Cy5),
and the expression level of each miRNA was calculated as
the ratio of the intensities for each sample to the refer-
ence. We then calculated the relative expression of each
miRNA in each cell line by normalizing to the overall sig-
nal observed for each cell line measurement, and aver-
aged duplicate spots and replicate cell line
measurements.
Hierarchical clustering analysis
The miRNA expression data was log-transformed, nor-
malized by median centering, and then clustered using
the Cluster and TreeView software packages [24]. The
entire dataset was clustered both on cell lines and on
miRNAs using average linkage hierarchical clustering
based on Pearson correlation.
Linear discriminant analysis
We defined three groups of cell lines based on annotated
histology of the tumor from which the cell line was
derived {SCLC, NSCLC and HBEC}. Each cell line can be
considered a point in the multi-dimensional space
defined by the miRNA expression. Given the assignment
of the cell lines into the three groups, we applied linear
discriminant analysis (LDA, using the "lda" function as
implemented in the R package MASS) [25,26], which
attempts to maximize the ratio of between-group vari-
ance to within-group variance of the dataset. The result is
a linear combination of features that characterize or sepa-
rate the groups and can be used to reduce the dimension-
ality of the data and to visualize the relationships between
the groups in expression space.
Statistical analysis
The significance of differential expression of individual
miRNAs between the groups was determined by two-
tailed unpaired t-test, correcting for multiple compari-
sons using the Benjamini-Hochberg false discovery rate
(FDR) method [27]. The trend in expression of each
miRNA across the three groups of cell lines was tested
using the Jonckheere-Terpstra test, a non-parametric test
for ordered differences among groups [28]. It is designed
to detect alternatives of ordered group differences with
expression of an individual miRNA increasing or decreas-
ing monotonically across the three ordered groups
(SCLCs, NSCLCs and HBECs), which can be expressed as
μSCLC ≤ μNSCLC ≤ μHBEC (or μSCLC ≥ μNSCLC ≥ μHBEC), with at
least one of the inequalities being strict, where μi denotes
the mean expression of a given miRNA in group i.Du et al. Journal of Experimental & Clinical Cancer Research 2010, 29:75
http://www.jeccr.com/content/29/1/75
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Results
Hierarchical clustering classifies cell lines as distinct groups 
that are consistent with their histological classification
In order to examine whether miRNA expression is infor-
mative in distinguishing SCLC cells from NSCLC cells as
well as normal lung cells, we measured the expression
levels of 136 miRNAs in a panel of cell lines by miRNA
microarray. The panel comprised three groups of cell
lines that were derived from human lung tumors or nor-
mal human lung tissue, including 9 SCLC cell lines, 7
NSCLC cell lines and 3 HBEC lines (Table 1). After nor-
malization, we clustered the miRNA expression data
using unsupervised clustering. As shown in Figure 1, the
overall expression profile divides the cell lines into two
large groups, recapitulating the histological classification
of the cell lines and separating the group of SCLC cell
lines from the group of NSCLC and HBEC cell lines. This
indicates that the SCLC cell lines have a distinct expres-
sion profile from that of NSCLCs and normal HBECs. In
addition, the NSCLCs cluster separately from the HBECs,
indicating that expression of specific miRNAs can also
classify NSCLCs from HBECs, which is consistent with a
previous report [29].
Specific miRNAs are expressed at significantly different 
levels between the lung cancer cell lines and HBECs as well 
as between the lung cancer subtypes
While the overall miRNA expression profile clusters the
cell lines into groups that are consistent with histological
features, the determinants of that clustering are individ-
ual miRNAs that are differentially expressed between the
groups. Such differentially expressed miRNAs have the
potential to serve as diagnostic markers of lung cancer as
well as of specific histological subtypes. In order to iden-
tify microRNAs with significant differential expression in
lung cancer cells relative to HBECs as well as between
Table 1: Histological classification of the lung cancer cell lines
Cell Line Tumor Subtype Age Ethnicity Gender Source Site
NCI-H146 SCLC 59 Caucasian M metastasis bone
NCI-H187 SCLC 47 Caucasian M metastasis pleural
NCI-H209 SCLC 55 Caucasian M metastasis bone
NCI-H526 SCLC 55 Caucasian M metastasis bone
NCI-H889 SCLC 69 Caucasian F metastasis lymph
NCI-H1672 SCLC 58 Caucasian M primary lung
NCI-H2107 SCLC 36 Black M metastasis bone
NCI-H2171 SCLC 50 Caucasian M metastasis pleural
NCI-H2195 SCLC 67 Caucasian M metastasis bone
NCI-H157 NSCLC (squamous) 59 Caucasian M metastasis pleural
NCI-H1819 NSCLC 
(adenocarcinoma)
55 Caucasian F metastasis lymph
NCI-H2052 NSCLC 
(mesothelioma)
65 Caucasian M metastasis pleural
NCI-H2887 NSCLC (squamous) 31 unknown M primary lung
HCC366 NSCLC 
(adenosquamous)
80 unknown F primary lung
HCC1195 NSCLC 
(adenocarcinoma)
47 Black M primary lung
HCC2450 NSCLC (squamous) 52 Caucasian M primary lung
HBEC2-KT Immortalized 
Normal
68 M NA lung
HBEC3-KT Immortalized 
Normal
65 F NA lung
HBEC4-KT Immortalized 
Normal
71 F NA lung
The lung cancer cell lines were established from tissue specimens obtained from lung cancer patients [73]. The subtype of each lung cancer 
cell line is based on histological examination of the tumor from which the line was derived. Patient age, ethnicity, and gender are listed along 
with the source of the tissue sample and the site from which the sample was derived.Du et al. Journal of Experimental & Clinical Cancer Research 2010, 29:75
http://www.jeccr.com/content/29/1/75
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lung cancer cell subtypes, we divided the set of cell lines
into three groups according to the histological classifica-
tion of the cell lines and the hierarchical clustering
results: SCLC (9 samples), NSCLC (7 samples) and HBEC
(3 samples), and assessed differential expression of indi-
vidual miRNAs between the groups by t-test.
Our results identified more miRNAs as classifying
SCLC cells from HBECs than as classifying NSCLC cells
from HBECs. As shown in Figure 2A, 30 miRNAs were
significantly differentially expressed between the SCLC
and HBEC cell lines at an FDR-corrected threshold of
0.05, with 16 miRNAs over-expressed and 14 miRNAs
under-expressed in SCLC compared to HBECs. Only two
miRNAs (miR-31 and miR-205) were significantly differ-
entially expressed between the NSCLC and HBEC cell
lines, as shown in Figure 2B. The comparison between
SCLC and NSCLC cell lines is shown in Figure 2C. 29
miRNAs were significantly differentially expressed
between the SCLC and NSCLC cell lines, of which 19 are
over-expressed in SCLC cell lines relative to NSCLCs and
10 are under-expressed. The miRNAs that are identified
as differentially expressed between SCLC cells and
NSCLC cells may serve as diagnostic markers for distin-
guishing SCLC from NSCLC lung tumors.
The miRNA expression profile changes progressively from 
normal cells to NSCLC to SCLC cells
Interestingly, the above analysis indicates that more miR-
NAs are differentially expressed between SCLC cell lines
and HBECs than between NSCLC cell lines and HBECs.
In addition, the two miRNAs that are significantly differ-
entially expressed in NSCLCs relative to HBECs are
included in the group of 30 miRNAs identified as differ-
entially expressed in SCLCs relative to HBECS, as shown
in Figure 2A. This suggests a possible pathological rela-
tionship between the three groups of cell lines. To exam-
ine this relationship, we applied linear discriminant
analysis to the three groups of cell lines based on the 41
miRNAs that are identified as significantly differentially
expressed as shown in Figure 2. As shown in Figure 3,
88% of the between-group variance is explained by the
first discriminant function with miRNA expression plac-
ing NSCLCs between HBECs and SCLC lung tumor cells,
suggesting a progressive change in expression from
HBECs to NSCLC to SCLC cell lines.
T o examine this relationship at the level of individual
microRNAs, we applied the Jonckheere-Terpstra test for
ordered means to the expression levels of each miRNA in
the three groups. This allowed us to assess whether or not
the expression trend followed the order {SCLC, NSCLC,
HBEC}. As shown in Table 2, of the 26 miRNAs that are
over-expressed in SCLC cell lines relative to non-SCLC
cell lines, all 26 (100%) show ordered expression at a sig-
nificance level of 0.05, with 24 (92%) showing strict
ordering of mean expression levels with SCLC > NSCLC
> HBEC. Of the 15 miRNAs that are under-expressed in
SCLC cell lines relative to non-SCLCs, 14 (93%) show
ordered expression at a significance level of 0.05, with 10
(66%) showing strict ordering of mean expression levels
with SCLC < NSCLC < HBEC. These results suggest that
expression of a set of miRNA changes progressively from
normal cells to NSCLC tumor cells to SCLC tumor cells.
Discussion
miRNAs have been intensively investigated as diagnostic
markers in various cancers and cancer subtypes [5,6,30].
However, few studies have specifically investigated the
diagnostic value of miRNA profiles in SCLCs. In this
s t u d y ,  w e  s h o w  t h a t  m o r e  m i R N A s  a r e  d i f f e r e n t i a l l y
expressed between SCLC cell lines and HBECs than
between NSCLC cell lines and HBECs; only two miRNAs
were significantly differentially expressed between the
NSCLCs and HBEC cell lines. The similarity between the
HBEC and NSCLC miRNA profiles reflects the close his-
tological relationship between HBECs and NSCLCs [31-
Figure 1 Clustering of cell lines by miRNA expression distinguishes SCLC cell lines from NSCLCs and normal HBECs. Shown is a heatmap rep-
resentation of the expression of 136 miRNAs in 19 cell lines, with blue indicating relative under-expression and yellow indicating relative over-expres-
sion. (S, SCLC; N, NSCLC; H, HBEC).
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33]. On the other hand, the distinctive miRNA expression
signature of SCLCs as compared with NSCLCs and
HBECs suggests the possibility of developing miRNA
profiling as a diagnostic tool for distinguishing SCLCs
from NSCLCs and normal lung tissues. The development
of miRNA profiling as a diagnostic tool could potentially
benefit SCLC diagnosis from two perspectives. First,
miRNA profiling would add a more quantitative aspect to
the diagnosis of SCLC. Although the SCLCs share com-
mon genetic abnormalities and histological features and
represent the most aggressive subtype of lung cancer in
general, the survival and prognosis of SCLC patients
diagnosed at the same stage vary [34,35], suggesting that
quantitative molecular traits are related to the degree of
malignancy. However, current diagnosis of SCLC is pri-
marily determined histologically [36], which is not suffi-
cient to quantitatively evaluate malignancy and
prognosis. Several studies have shown that miRNA
expression levels are related to cancer prognosis [37-40].
Similarly, the quantification of aberrant expression levels
of miRNAs in SCLCs may serve as a reliable tool for the
prediction of SCLC prognosis. Second, the miRNAs iden-
tified as over-expressed in SCLCs may serve as early and
non-invasive detection markers. Recent findings have
shown that miRNAs are secreted into blood and are
detectable in serum, showing potential as non-invasive
markers for diseases [41,42]. Inexpensive, non-invasive
detection methods are suitable for the development of
large-scale screening of high-risk populations and may
therefore significantly advance the early diagnosis of can-
cers. Given the aggressive nature of most SCLCs, the
development of highly sensitive and specific non-invasive
molecular diagnostics based on miRNA profiling could
be of great clinical benefit. Overall, the miRNAs identi-
f i e d  a s  d i f f e r e n t i a l l y  e x p r e s s e d  i n  S C L C  c o m p a r e d  t o
NSCLC and normal cells hold promise as early, noninva-
sive and quantitative markers of SCLCs and warrant fur-
ther investigation.
Figure 2 Specific miRNAs are differentially expressed between SCLC, NSCLC and HBEC cell lines. We divided the cell lines into three groups: 
SCLC (9 samples), NSCLC (7 samples), and HBECs, compared the groups pairwise, and assessed the significance of differential expression of each miR-
NA. (A) miRNAs that are differentially expressed between SCLCs and HBECs. (B) miRNAs that are differentially expressed between NSCLCs and HBECs. 
(C) miRNAs that are differentially expressed between SCLCs and NSCLCs. Yellow indicates relative over-expression, and blue indicates relative under-
expression.
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Our results suggest that miRNAs may play an impor-
tant role in the pathogenesis of SCLCs. Although there is
evidence to support NSCLCs as originating from HBECs
[31-33], the findings on the histological origin of SCLC
remain somewhat controversial [43-45]. Previous studies
suggest that a transition between NSCLC and SCLC can
occur during lung tumor progression and that neuroen-
docrine differentiation of NSCLCs, which has been pos-
tulated to be an intermediate step between NSCLC and
SCLC, is related to poor prognosis and early metastasis
[46-48]. However, the mechanisms involved in this transi-
tion between the two subtypes are not completely under-
stood. Our results show that of the 41 miRNAs that are
differentially expressed between the three groups of cell
lines, 34 (83%) show a trend of progressive differential
expression from HBECs to NSCLCs to SCLCs (Table 2).
These results support the hypothesis that differential
expression of miRNAs could contribute to the differentia-
tion of lung cancer cells from one subtype to another, in
which SCLC could result from NSCLC cells by gradually
acquiring SCLC properties through the cumulative dys-
regulation of miRNAs, and that manipulating the levels of
specific miRNAs levels might prevent the differentiation
of lung cancer cells toward a more malignant phenotype.
Changes in miRNA expression can lead to tumorigene-
sis, but the many complex interactions between miRNAs
Figure 3 A sequential change in expression profile from normal cells to NSCLC cells to SCLC cells. Linear discriminant analysis places the 
NSCLCs between SCLCs and HBECs, suggesting a progression from HBECs to NSCLC to SCLC cell lines. The plot is a projection of the multi-dimensional 
space into two dimensions described by two linear discriminants, in which the individual points represent the cell lines and the classifiers are indicated 
by black lines. 88% of the between-class variance is explained by the first discriminant function (displayed along the x-axis of the plot).
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Table 2: Sequential changes in expression of individual miRNAs that are differentially expressed between the cell line groups
miRNA SCLC NSCLC HBEC SCLC 
NSCLC
SCLC 
HBEC
NSCLC 
HBEC
p SCLC 
NSCLC
p SCLC HBEC p NSCLC 
HBEC
pJT Location
Over-expressed in SCLC cell lines
miR-338 0.47 ± 0.16 0.08 ± 0.04 0.01 ± 0.00 5.71 47.33 8.29 1.62E-03 8.08E-03 2.38E-01 1.99E-05 17q25.3
miR-101 2.46 ± 1.10 0.52 ± 0.25 0.25 ± 0.08 4.72 9.72 2.06 5.22E-03 3.50E-02 4.20E-01 6.41E-05 1p31.3,9p24.1
miR-98 1.79 ± 0.86 0.51 ± 0.27 0.62 ± 0.11 3.52 2.91 0.83 1.56E-02 1.12E-01 7.49E-01 8.96E-03 Xp11.22
miR-106b 0.47 ± 0.20 0.15 ± 0.08 0.07 ± 0.01 3.26 6.78 2.08 1.03E-02 3.41E-02 4.20E-01 3.31E-05 7q22.1
miR-17-5p 1.07 ± 0.57 0.33 ± 0.19 0.29 ± 0.07 3.25 3.72 1.15 2.95E-02 1.12E-01 8.56E-01 9.49E-04 13q31.3
miR-106a 1.26 ± 0.59 0.41 ± 0.23 0.31 ± 0.05 3.10 4.06 1.31 1.96E-02 7.11E-02 7.39E-01 6.25E-04 Xq26.2
miR-96 0.73 ± 0.28 0.26 ± 0.10 0.12 ± 0.05 2.77 6.24 2.25 1.03E-02 3.14E-02 3.36E-01 4.62E-05 7q32.2
miR-15a 0.45 ± 0.15 0.17 ± 0.04 0.18 ± 0.08 2.63 2.55 0.97 5.12E-03 5.48E-02 9.39E-01 3.49E-03 13q14.3
miR-92 0.44 ± 0.17 0.17 ± 0.08 0.15 ± 0.04 2.54 2.96 1.16 1.33E-02 5.48E-02 7.91E-01 5.42E-04 Xq26.2
miR-326 0.49 ± 0.20 0.20 ± 0.11 0.05 ± 0.01 2.49 10.45 4.19 2.45E-02 2.71E-02 3.36E-01 1.04E-04 11q13.4
miR-1 0.09 ± 0.03 0.04 ± 0.03 0.01 ± 0.01 2.40 6.42 2.68 3.92E-02 2.71E-02 5.04E-01 1.24E-03 20q13.33,18q11.2
miR-15b 0.63 ± 0.24 0.26 ± 0.09 0.23 ± 0.10 2.39 2.78 1.17 1.56E-02 7.07E-02 7.75E-01 2.72E-03 3q26.1
miR-195 2.74 ± 1.23 1.19 ± 0.45 0.60 ± 0.06 2.30 4.55 1.98 3.51E-02 5.48E-02 3.36E-01 4.06E-04 17p13.1
miR-103 0.91 ± 0.26 0.41 ± 0.11 0.29 ± 0.07 2.23 3.16 1.42 5.12E-03 1.99E-02 4.20E-01 7.54E-05 5q35.1,20p13
miR-135 0.28 ± 0.12 0.13 ± 0.03 0.08 ± 0.02 2.19 3.41 1.56 2.95E-02 6.50E-02 3.36E-01 2.25E-04 3p21.1,12q23.1
miR-301 0.74 ± 0.28 0.35 ± 0.44 0.05 ± 0.02 2.12 15.95 7.53 1.14E-01 1.68E-02 5.04E-01 2.72E-03 17q22,22q11.21
miR-328 0.76 ± 0.31 0.36 ± 0.19 0.04 ± 0.03 2.12 19.06 9.00 4.42E-02 2.24E-02 2.38E-01 1.42E-04 16q22.1
miR-93 0.94 ± 0.38 0.45 ± 0.09 0.42 ± 0.13 2.07 2.23 1.07 2.95E-02 1.12E-01 7.94E-01 8.27E-04 7q22.1
miR-16 1.04 ± 0.40 0.51 ± 0.15 0.33 ± 0.10 2.03 3.14 1.55 2.95E-02 5.48E-02 4.20E-01 5.42E-04 13q14.3,3q26.1
miR-324-5p 0.43 ± 0.16 0.22 ± 0.22 0.09 ± 0.03 1.95 4.80 2.46 1.14E-01 3.18E-02 5.93E-01 1.24E-03 17p13.1
miR-107 0.71 ± 0.13 0.38 ± 0.13 0.27 ± 0.09 1.86 2.62 1.41 4.74E-03 4.78E-03 4.64E-01 1.66E-04 10q23.31
miR-149 0.24 ± 0.08 0.15 ± 0.12 0.07 ± 0.03 1.56 3.58 2.29 2.12E-01 3.18E-02 4.99E-01 5.02E-03 2q37.3
miR-181c 0.39 ± 0.12 0.25 ± 0.12 0.13 ± 0.07 1.52 2.91 1.91 1.14E-01 3.20E-02 4.26E-01 4.45E-03 19p13.12
miR-148b 0.24 ± 0.10 0.17 ± 0.11 0.06 ± 0.04 1.39 4.24 3.05 3.38E-01 4.69E-02 4.20E-01 5.00E-02 12q13.13
miR-142-3p 0.13 ± 0.05 0.10 ± 0.07 0.03 ± 0.02 1.31 4.03 3.09 4.11E-01 4.46E-02 4.20E-01 1.72E-02 17q22
miR-30c 2.97 ± 0.87 2.47 ± 1.34 1.12 ± 0.09 1.20 2.65 2.20 4.72E-01 3.18E-02 4.20E-01 5.00E-02 1p34.2,6q13D
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Under-expressed in SCLC cell lines
miR-199a* 0.16 ± 0.11 0.28 ± 0.28 0.74 ± 0.18 0.56 0.21 0.37 3.72E-01 1.43E-03 2.73E-01 2.11E-02 19p13.2,1q24.3
miR-27a 0.31 ± 0.23 0.74 ± 0.27 0.90 ± 0.10 0.42 0.35 0.83 2.73E-02 1.86E-02 6.07E-01 1.42E-03 19p13.12
miR-23b 1.86 ± 0.79 5.29 ± 1.55 5.89 ± 0.65 0.35 0.32 0.90 1.99E-03 4.21E-04 7.49E-01 1.93E-04 9q22.32
miR-222 0.47 ± 0.46 1.33 ± 1.07 2.40 ± 0.67 0.35 0.19 0.55 1.14E-01 3.23E-03 4.26E-01 1.09E-03 Xp11.3
miR-221 0.77 ± 0.83 2.19 ± 1.44 3.51 ± 1.17 0.35 0.22 0.62 9.69E-02 1.10E-02 4.64E-01 6.25E-04 Xp11.3
miR-99a 0.28 ± 0.19 0.85 ± 0.70 0.93 ± 0.20 0.33 0.30 0.91 1.03E-01 5.64E-03 9.25E-01 8.00E-03 21q21.1
miR-24 0.62 ± 0.39 1.93 ± 0.70 2.05 ± 0.12 0.32 0.30 0.94 5.12E-03 2.80E-03 8.76E-01 8.27E-04 9q22.32,19p13.12
miR-29c 0.56 ± 0.20 1.97 ± 1.13 1.59 ± 0.71 0.29 0.36 1.24 1.75E-02 1.68E-02 7.86E-01 1.25E-02 1q32.2
miR-23a 1.19 ± 0.74 4.32 ± 1.83 5.76 ± 0.96 0.27 0.21 0.75 5.12E-03 2.50E-04 4.97E-01 4.70E-04 19p13.12
miR-205 0.45 ± 0.15 1.86 ± 3.04 18.38 ± 4.63 0.24 0.02 0.10 3.03E-01 9.67E-06 9.08E-03 1.79E-01 1q32.2
miR-29b 0.72 ± 0.33 3.07 ± 1.49 2.31 ± 1.38 0.23 0.31 1.33 5.22E-03 3.18E-02 7.14E-01 8.00E-03 7q32.3,1q32.2
miR-29a 0.75 ± 0.29 4.08 ± 2.53 3.73 ± 1.63 0.18 0.20 1.09 1.27E-02 3.23E-03 9.07E-01 6.36E-03 7q32.3
miR-22 0.05 ± 0.02 0.33 ± 0.07 0.24 ± 0.12 0.16 0.22 1.39 3.55E-06 5.64E-03 4.26E-01 1.85E-03 17p13.3
miR-21 4.35 ± 6.37 27.93 ± 10.26 11.01 ± 4.60 0.16 0.39 2.54 1.99E-03 2.23E-01 2.73E-01 1.91E-02 17q23.1
miR-31 0.04 ± 0.06 0.64 ± 0.39 5.65 ± 0.96 0.07 0.01 0.11 5.22E-03 3.85E-07 2.34E-04 2.25E-04 9p21.3
Shown are the mean expression level of each miRNA in SCLC, NSCLC, and HBEC cell lines, p values from two-sided t-tests comparing expression for each miRNA between the three groups, corrected 
for multiple comparisons using the Benjamini and Hochberg FDR method [27], and p values from the Jonckheere-Terpstra test for ordered alternatives (pJT). The last column contains the 
chromosomal location.
Table 2: Sequential changes in expression of individual miRNAs that are differentially expressed between the cell line groups (Continued)Du et al. Journal of Experimental & Clinical Cancer Research 2010, 29:75
http://www.jeccr.com/content/29/1/75
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and their targets that occur during these processes are
not fully understood. A variety of studies have linked
miRNA dysregulation with malignant transformation
[49]. However, the role of miRNAs in SCLC pathogenesis
has not been extensively studied. Our investigation iden-
tified a group of miRNAs that show a progressive differ-
ential expression from HBECs to NSCLC and SCLC cells.
Several of the miRNAs identified in this study have been
shown to be associated with various cancer types in pre-
vious studies. For example, we found significant overex-
pression of miR-103, miR-107, miR-301 and miR-338 in
lung cancer cells as compared to HBECs. These miRNAs
have been shown to be over-expressed in several types of
cancers including lung cancers [17,50,51], and high
expression of miR-103 and miR-107 were correlated with
poor survival in cancer patients (esophageal squamous
and pancreatic tumors) [51,52]. These miRNAs might
contribute to common pathways during the transforma-
tion of normal cells to tumor cells during lung cancer
pathogenesis, and the greater extent of aberrant expres-
sion of these miRNAs in SCLCs relative to NSCLCs
might contribute to the more aggressive phenotype of the
former.
Our study also identified a group of miRNAs that might
contribute to the establishment of SCLC features and the
specific phenotypes that differentiate SCLC from
NSCLC. For example, we found over-expression of miR-
17-5p in SCLCs compared to NSCLCs. This miRNA was
recently shown to target Rbl2, a member of the Rb family
[53]. Rb is a tumor suppressor that induces arrest of the
cell cycle at G1 [54]. SCLCs have been shown to exhibit
loss of Rb expression in 87-100% of tumors compared to
less than 15% in NSCLC [55-57]. SCLC cells were also
previously shown to be addicted to continued over-
expression of miR-17-5p [58], and forced over-expression
of the miRNA cluster that includes miR-17-5p (miR-17-
92) was shown to induce embryonic lung epithelial cell
proliferation [59]. Coupled with these data, our results
suggest that dysregulation of this miRNA could be an
important distinction that defines the pathogenesis and
phenotypic characteristics of SCLC compared to NSCLC.
We also observed a significant increase in miR-135
expression in SCLC cells compared to NSCLC cells. miR-
135 has recently been shown to inhibit expression of the
tumor suppressor gene Adenomatous Polyposis Coli
(APC) in colorectal cancer [60]. Loss of heterozygosity of
APC has been shown in both small cell and non-small cell
lung cancers, but appears to be more frequent in SCLC
[61]. Silencing of this gene by CpG hypermethylation,
however, is more frequent in NSCLC compared to SCLC
[62], suggesting that various lung tumor subtypes could
use different means to down-regulate this tumor suppres-
sor. These findings suggest that SCLC preferentially uti-
lizes microRNA-based regulatory mechanisms to reduce
APC expression. miR-29a, -29b and -29c expression was
shown be significantly down-regulated in SCLC cells
compared to HBECs, whereas these reductions were not
seen in NSCLC cells. Expression levels of miR-29a, miR-
29b, and miR-29c were previously shown to be inversely
correlated with levels of DNA methyltransferase
(DNMT) -3A and -3B [14], two key enzymes involved in
DNA methylation that have been shown to promote tum-
origenesis [63]. Forced expression of these miRNAs also
inhibited tumorigenicity in vitro and  in vivo [14]. In
SCLC cells, but not NSCLC cells, we also observed signif-
icant reductions in miR-24, inhibition of which was pre-
viously shown to enhance cell proliferation [64]. These
miRNAs might contribute to the specific pathogenesis
pathways during the transformation of SCLCs but not
NSCLCs.
Several miRNAs identified in our study exhibited
expression levels not consistent with previous observa-
tions in other cancer types, suggesting contextual depen-
dence of miRNA function in the regulation of
tumorigenesis pathways. For example, we observed sig-
nificantly increased levels of miR-148b in SCLC com-
pared to HBECs; miR-148b has been shown to target
DNMT3B [65], with down-regulation of miR-148b
observed in metastatic cancers [66]. miR-21, miR-221
and miR-222, which have been shown to be oncogenic
m i R N A s  a n d  u p - r e g u l a t e d  i n  c e r t a i n  l u n g  c a n c e r  s u b -
types [67,68], are significantly down-regulated in SCLC.
We speculate that these miRNAs may not be the primary
driving force for controlling SCLC cell proliferation and
survival. Given the large number of miRNAs that are
found aberrantly expressed in SCLCs, it is possible that
some of these miRNAs play crucial roles in pathogenesis
of SCLC. The oncogenic pathways up-regulated by these
miRNAs might lead to feedback up-regulation of certain
tumor suppressor miRNAs and down-regulation of cer-
tain oncogenic miRNAs. Further studies are certainly
needed to address this question. We also observed up-
regulation of miR-142-3p in SCLC compared to HBECs,
although a previous report showed significant repression
of this miRNA in lung adenocarcinomas versus normal
tissue [69]. Another study showed down-regulation of
this miRNA early in tumor development followed by
increased expression at the later stages of lung tumori-
genesis [70]. Expression levels of this miRNA could there-
f o r e  v a r y  b o t h  w i t h  l u n g  t u m o r  s u b t y p e  a n d  s t a g e  o f
tumor development. miR-1 has also been shown to be
expressed at lower levels in lung cancer cell lines, includ-
ing both NSCLC and SCLC, than in bronchial epithelial
cells [71], whereas our results show significant over-
expression of miR-1 in lung cancer cell lines compared to
HBECs. However, given the extremely low expression lev-
els observed in both the normal bronchial epithelial cells
and lung cancer cells in our study, and in normal lung tis-Du et al. Journal of Experimental & Clinical Cancer Research 2010, 29:75
http://www.jeccr.com/content/29/1/75
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sues in other studies [71,72], the aberrant expression of
miR-1 in lung cancers relative to normal lung cells needs
to be evaluated further.
Conclusions
In summary, our study raises several interesting ques-
tions regarding the role of miRNAs in pathogenesis and
diagnosis of SCLC. We addressed the potential of miRNA
profiling as a diagnostic tool for distinguishing SCLC
from NSCLC and normal lung epithelial cells. In addi-
tion, our study revealed for the first time that the group of
miRNAs that are differentially expressed between lung
cancer cell lines and normal lung epithelial cells shows a
trend from HBECs to NSCLC cells to SCLC cells, sug-
gesting that increased dysregulation of miRNA expres-
sion might be involved in the progression of lung tumors
toward a more malignant subtype. Further study on a
larger scale is certainly needed to fully define the poten-
tial of miRNAs as diagnostic markers of SCLC, as well as
the role of specific miRNAs in the pathogenesis of SCLC.
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